Table of Contents Author Guidelines Submit a Manuscript
Gastroenterology Research and Practice
Volume 2016 (2016), Article ID 5397407, 6 pages
http://dx.doi.org/10.1155/2016/5397407
Research Article

Response to Pegylated Interferon Plus Ribavirin in Patients with Hepatitis C Virus Genotype 6a Infection from Guangdong and Guangxi Province of China

1Ruikang Hospital Affiliated to Guangxi University of Chinese Medicine, Nanning 530000, China
2Department of Infectious Diseases, the Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510080, China
3Pingguo County People’s Hospital, Guangxi 531400, China
4Department of Emergency, Affiliated Liuzhou Hospital of Guangxi Traditional Chinese Medicine University, Guangxi 545007, China

Received 18 July 2015; Revised 31 October 2015; Accepted 4 November 2015

Academic Editor: Paolo Gionchetti

Copyright © 2016 Wangxia Tong et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. Kumar and I. M. Jacobson, “Antiviral therapy with nucleotide polymerase inhibitors for chronic hepatitis C,” Journal of Hepatology, vol. 61, no. 1, pp. S91–S97, 2014. View at Publisher · View at Google Scholar · View at Scopus
  2. F. Poordad, K. R. Reddy, and P. Martin, “Rapid virologic response: a new milestone in the management of chronic hepatitis C,” Clinical Infectious Diseases, vol. 46, no. 1, pp. 78–84, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. C. H. Liu, C. J. Liu, C. L. Lin et al., “Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial,” Clinical Infectious Diseases, vol. 47, no. 10, pp. 1260–1269, 2008. View at Publisher · View at Google Scholar
  4. P. Simmonds, J. Bukh, C. Combet et al., “Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes,” Hepatology, vol. 42, no. 4, pp. 962–973, 2005. View at Publisher · View at Google Scholar · View at Scopus
  5. V. H. Pham, H. D. P. Nguyen, P. T. Ho et al., “Very high prevalence of hepatitis C virus genotype 6 variants in southern Vietnam: large-scale survey based on sequence determination,” Japanese Journal of Infectious Diseases, vol. 64, no. 6, pp. 537–539, 2011. View at Google Scholar · View at Scopus
  6. L. Lu, M. Wang, W. Xia et al., “Migration patterns of hepatitis C virus in China characterized for five major subtypes based on samples from 411 volunteer blood donors from 17 provinces and municipalities,” Journal of Virology, vol. 88, no. 13, pp. 7120–7129, 2014. View at Publisher · View at Google Scholar · View at Scopus
  7. X. Rong, R. Xu, H. Xiong et al., “Increased prevalence of hepatitis C virus subtype 6a in China: a comparison between 2004–2007 and 2008–2011,” Archives of Virology, vol. 159, no. 12, pp. 3231–3237, 2014. View at Publisher · View at Google Scholar · View at Scopus
  8. L. Gu, W. Tong, M. Yuan, T. Lu, C. Li, and L. Lu, “An increased diversity of HCV isolates were characterized among 393 patients with liver disease in China representing six genotypes, 12 subtypes, and two novel genotype 6 variants,” Journal of Clinical Virology, vol. 57, no. 4, pp. 311–317, 2013. View at Publisher · View at Google Scholar · View at Scopus
  9. G. W. McCaughan, M. Omata, D. Amarapurkar et al., “Asian Pacific Association for the Study of the Liver consensus statements on the diagnosis, management and treatment of hepatitis C virus infection,” Journal of Gastroenterology and Hepatology, vol. 22, no. 5, pp. 615–633, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. P. T. Thu Thuy, C. Bunchorntavakul, H. Tan Dat, and K. Rajender Reddy, “A randomized trial of 48 versus 24 weeks of combination pegylated interferon and ribavirin therapy in genotype 6 chronic hepatitis C,” Journal of Hepatology, vol. 56, no. 5, pp. 1012–1018, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. Y. Q. Zhou, X. H. Wang, G. H. Hong et al., “Twenty-four weeks of pegylated interferon plus ribavirin effectively treat patients with HCV genotype 6a,” Journal of Viral Hepatitis, vol. 18, no. 8, pp. 595–600, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. A. Mangia, R. Santoro, N. Minerva et al., “Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3,” The New England Journal of Medicine, vol. 352, no. 25, pp. 2609–2617, 2005. View at Publisher · View at Google Scholar · View at Scopus
  13. N. H. Nguyen, P. VuTien, R. T. Garcia et al., “Response to pegylated interferon and ribavirin in Asian American patients with chronic hepatitis C genotypes 1 vs 2/3 vs 6,” Journal of Viral Hepatitis, vol. 17, no. 10, pp. 691–697, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. L. Lu, T. Nakano, Y. He, Y. Fu, C. H. Hagedorn, and B. H. Robertson, “Hepatitis C virus genotype distribution in China: predominance of closely related subtype 1b isolates and existence of new genotype 6 variants,” Journal of Medical Virology, vol. 75, no. 4, pp. 538–549, 2005. View at Publisher · View at Google Scholar · View at Scopus
  15. M. Lemoine, S. Katsahian, M. Ziol et al., “Liver stiffness measurement as a predictive tool of clinically significant portal hypertension in patients with compensated hepatitis C virus or alcohol-related cirrhosis,” Alimentary Pharmacology and Therapeutics, vol. 28, no. 9, pp. 1102–1110, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. A. Mangia, F. Bandiera, G. Montalto et al., “Individualized treatment with combination of Peg-interferon alpha 2b and ribavirin in patients infected with HCV genotype 3,” Journal of Hepatology, vol. 53, no. 6, pp. 1000–1005, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. O. Dalgard, K. Bjoro, H. Ring-Larsen, and H. Verbaan, “In patients with HCV genotype 2 or 3 infection and RVR 14 weeks treatment is noninferior to 24 weeks. Pooled analysis of two Scandinavian trials,” European Journal of Gastroenterology and Hepatology, vol. 22, no. 5, pp. 552–556, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. S. Bruno, C. Cammà, V. Di Marco et al., “Peginterferon alfa-2b plus ribavirin for naïve patients with genotype 1 chronic hepatitis C: a randomized controlled trial,” Journal of Hepatology, vol. 41, no. 3, pp. 474–481, 2004. View at Publisher · View at Google Scholar · View at Scopus
  19. S. Missiha, J. Heathcote, T. Arenovich, K. Khan, and The Canadian Pegasys Expanded Access Group, “Impact of Asian race on response to combination therapy with peginterferon alfa-2a and ribavirin in chronic hepatitis C,” The American Journal of Gastroenterology, vol. 102, no. 10, pp. 2181–2188, 2007. View at Publisher · View at Google Scholar · View at Scopus
  20. K. K. Yan, M. Guirgis, T. Dinh et al., “Treatment responses in Asians and Caucasians with chronic hepatitis C infection,” World Journal of Gastroenterology, vol. 14, no. 21, pp. 3416–3420, 2008. View at Publisher · View at Google Scholar · View at Scopus